FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969296260> ?p ?o ?g. }

• W2969296260 endingPage "328.e1" @default.
• W2969296260 startingPage "321" @default.
• W2969296260 abstract "Background and Aims TC-325 (Hemospray; Cook Medical, Winston-Salem, NC, USA), an endoscopic hemostatic powder, exhibits possible benefits in patients with malignant GI bleeding. Our aim is to assess feasibility and determine estimates of efficacy of TC-325 compared with standard of care (SOC) in terms of initial hemostasis and recurrent bleeding rates in comparable groups of patients with malignant GI bleeding. Methods Adult patients presenting with acute malignant upper or lower GI bleeding were randomized to TC-325 or SOC. Measured outcomes included feasibility of recruitment and randomization in the urgent care setting, immediate hemostasis, recurrent bleeding, need for additional treatment modalities, and mortality. Results A preplanned 20 patients (upper GI source in 85%) were randomized 1:1 to TC-325 or SOC (25% women, age 67.2 ± 15.9 years, oozing in 95%) over 20 months. Immediate hemostasis was achieved in 90% of patients treated initially with TC-325 versus 40% in the SOC group (P = .057). Overall, 83.3% crossed over to TC-325, with hemostasis then achieved at index endoscopy in 80%. Overall, hemostasis at index endoscopy (before or after crossover) was obtained in 87.7% of patients treated with TC-325. Recurrent bleeding over the next 180 days was 20% in the TC-325 group compared with 60% in the SOC group (P = .170). Conclusions This pilot trial demonstrates the feasibility of TC-325 in malignant GI bleeding and provides results to help inform a larger randomized trial. Although not powered for such, results suggest that use of TC-325 is a very promising modality in malignant GI bleeding in achieving immediate hemostasis and may even result in decreased subsequent recurrent bleeding. (Clinical trial registration number: NCT02135627.) TC-325 (Hemospray; Cook Medical, Winston-Salem, NC, USA), an endoscopic hemostatic powder, exhibits possible benefits in patients with malignant GI bleeding. Our aim is to assess feasibility and determine estimates of efficacy of TC-325 compared with standard of care (SOC) in terms of initial hemostasis and recurrent bleeding rates in comparable groups of patients with malignant GI bleeding. Adult patients presenting with acute malignant upper or lower GI bleeding were randomized to TC-325 or SOC. Measured outcomes included feasibility of recruitment and randomization in the urgent care setting, immediate hemostasis, recurrent bleeding, need for additional treatment modalities, and mortality. A preplanned 20 patients (upper GI source in 85%) were randomized 1:1 to TC-325 or SOC (25% women, age 67.2 ± 15.9 years, oozing in 95%) over 20 months. Immediate hemostasis was achieved in 90% of patients treated initially with TC-325 versus 40% in the SOC group (P = .057). Overall, 83.3% crossed over to TC-325, with hemostasis then achieved at index endoscopy in 80%. Overall, hemostasis at index endoscopy (before or after crossover) was obtained in 87.7% of patients treated with TC-325. Recurrent bleeding over the next 180 days was 20% in the TC-325 group compared with 60% in the SOC group (P = .170). This pilot trial demonstrates the feasibility of TC-325 in malignant GI bleeding and provides results to help inform a larger randomized trial. Although not powered for such, results suggest that use of TC-325 is a very promising modality in malignant GI bleeding in achieving immediate hemostasis and may even result in decreased subsequent recurrent bleeding. (Clinical trial registration number: NCT02135627.)" @default.
• W2969296260 created "2019-08-29" @default.
• W2969296260 creator A5025156152 @default.
• W2969296260 creator A5051765373 @default.
• W2969296260 creator A5052819185 @default.
• W2969296260 creator A5056089657 @default.
• W2969296260 creator A5089206406 @default.
• W2969296260 date "2020-02-01" @default.
• W2969296260 modified "2023-10-14" @default.
• W2969296260 title "TC-325 hemostatic powder versus current standard of care in managing malignant GI bleeding: a pilot randomized clinical trial" @default.
• W2969296260 cites W1995461503 @default.
• W2969296260 cites W2017608824 @default.
• W2969296260 cites W2025184903 @default.
• W2969296260 cites W2043138736 @default.
• W2969296260 cites W2043387284 @default.
• W2969296260 cites W2067017222 @default.
• W2969296260 cites W2082051687 @default.
• W2969296260 cites W2085242635 @default.
• W2969296260 cites W2112091799 @default.
• W2969296260 cites W2114336220 @default.
• W2969296260 cites W2117957691 @default.
• W2969296260 cites W2122292928 @default.
• W2969296260 cites W2133116306 @default.
• W2969296260 cites W2133233018 @default.
• W2969296260 cites W2147615734 @default.
• W2969296260 cites W2277362275 @default.
• W2969296260 cites W2394962898 @default.
• W2969296260 cites W2530567935 @default.
• W2969296260 cites W2536599654 @default.
• W2969296260 cites W2563446817 @default.
• W2969296260 cites W2769151626 @default.
• W2969296260 cites W2779306262 @default.
• W2969296260 cites W2803325862 @default.
• W2969296260 cites W2803962350 @default.
• W2969296260 cites W2807616091 @default.
• W2969296260 cites W2822493674 @default.
• W2969296260 cites W4249335893 @default.
• W2969296260 doi "https://doi.org/10.1016/j.gie.2019.08.005" @default.
• W2969296260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31437456" @default.
• W2969296260 hasPublicationYear "2020" @default.
• W2969296260 type Work @default.
• W2969296260 sameAs 2969296260 @default.
• W2969296260 citedByCount "34" @default.
• W2969296260 countsByYear W29692962602020 @default.
• W2969296260 countsByYear W29692962602021 @default.
• W2969296260 countsByYear W29692962602022 @default.
• W2969296260 countsByYear W29692962602023 @default.
• W2969296260 crossrefType "journal-article" @default.
• W2969296260 hasAuthorship W2969296260A5025156152 @default.
• W2969296260 hasAuthorship W2969296260A5051765373 @default.
• W2969296260 hasAuthorship W2969296260A5052819185 @default.
• W2969296260 hasAuthorship W2969296260A5056089657 @default.
• W2969296260 hasAuthorship W2969296260A5089206406 @default.
• W2969296260 hasConcept C126322002 @default.
• W2969296260 hasConcept C141071460 @default.
• W2969296260 hasConcept C168563851 @default.
• W2969296260 hasConcept C204243189 @default.
• W2969296260 hasConcept C2778451229 @default.
• W2969296260 hasConcept C2778589496 @default.
• W2969296260 hasConcept C71924100 @default.
• W2969296260 hasConceptScore W2969296260C126322002 @default.
• W2969296260 hasConceptScore W2969296260C141071460 @default.
• W2969296260 hasConceptScore W2969296260C168563851 @default.
• W2969296260 hasConceptScore W2969296260C204243189 @default.
• W2969296260 hasConceptScore W2969296260C2778451229 @default.
• W2969296260 hasConceptScore W2969296260C2778589496 @default.
• W2969296260 hasConceptScore W2969296260C71924100 @default.
• W2969296260 hasIssue "2" @default.
• W2969296260 hasLocation W29692962601 @default.
• W2969296260 hasOpenAccess W2969296260 @default.
• W2969296260 hasPrimaryLocation W29692962601 @default.
• W2969296260 hasRelatedWork W1988356095 @default.
• W2969296260 hasRelatedWork W1999967090 @default.
• W2969296260 hasRelatedWork W2041828149 @default.
• W2969296260 hasRelatedWork W2134905817 @default.
• W2969296260 hasRelatedWork W2188642196 @default.
• W2969296260 hasRelatedWork W2414969066 @default.
• W2969296260 hasRelatedWork W2586650731 @default.
• W2969296260 hasRelatedWork W2925167642 @default.
• W2969296260 hasRelatedWork W2994435929 @default.
• W2969296260 hasRelatedWork W3125097634 @default.
• W2969296260 hasVolume "91" @default.
• W2969296260 isParatext "false" @default.
• W2969296260 isRetracted "false" @default.
• W2969296260 magId "2969296260" @default.
• W2969296260 workType "article" @default.